M-Xylene

M-Xylene

SCHEMBL18890231

Cc1cccc(C)c1.Cc1cccc(C)c1.S

nearest known ligand 0.92

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 6/20 0.92
ALDH1A1 P00352 2/20 0.58
MAPK1 P28482 1/20 0.58
TSHR P16473 2/20 0.50
TDP1 Q9NUW8 2/20 0.50
LMNA P02545 1/20 0.50
ALOX12 P18054 1/20 0.50
TP53 P04637 1/20 0.50
CYP1A2 P05177 2/20 0.48
NPC1 O15118 1/20 0.48
CASP3 P42574 1/20 0.48
SENP8 Q96LD8 1/20 0.48
SENP7 Q9BQF6 1/20 0.48
SENP6 Q9GZR1 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48
MAPT P10636 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
HTT P42858 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
M-Xylene SCHEMBL27645721 1.00
M-Xylene SCHEMBL6397624 0.96
M-Xylene SCHEMBL28189 0.96
M-Xylene SCHEMBL891494 0.96 ACHE (1.00) ACHEALDH1A1MAPK1TSHRTDP1
M-Xylene SCHEMBL28287184 0.93 ACHE (0.80) ACHEALDH1A1MAPK1TSHRTDP1
M-Xylene SCHEMBL4596533 0.92 ACHE (0.92) ACHEALDH1A1MAPK1TSHRTDP1
M-Xylene SCHEMBL2292576 0.92 ACHE (0.92) ACHEALDH1A1MAPK1TSHRTDP1
M-Xylene SCHEMBL6772614 0.92
M-Xylene SCHEMBL78260 0.92 ACHE (0.92) ACHEALDH1A1MAPK1TSHRTDP1
M-Xylene SCHEMBL18045662 0.92

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3383421-B1 STAPLED HELICAL PEPTIDES AND METHODS OF SYNTHESIS UNIV HONG KONG (CN) 2021-05-19 EP disclosed
US-10954287-B2 Ras binding peptides and methods of use RA PHARMACEUTICALS, INC. (US) 2021-03-23 US disclosed
US-20190119358-A1 RAS BINDING PEPTIDES AND METHODS OF USE RA PHARMACEUTICALS, INC. 2019-04-25 US disclosed
EP-3442991-A1 RAS BINDING PEPTIDES AND METHODS OF USE RA Pharmaceuticals, Inc. (US) 2019-02-20 EP disclosed
CN-109069581-A lock ring helical peptide and synthetic method 香港大学 2018-12-21 CN disclosed
EP-3383421-A1 STAPLED HELICAL PEPTIDES AND METHODS OF SYNTHESIS The University of Hong Kong (CN) 2018-10-10 EP disclosed
US-10011631-B2 Stapled helical peptides and methods of synthesis THE UNIVERSITY OF HONG KONG (HK) 2018-07-03 US disclosed
WO-2017181061-A1 RAS BINDING PEPTIDES AND METHODS OF USE RA PHARMACEUTICALS, INC. (US) 2017-10-19 WO disclosed
WO-2017092691-A1 STAPLED HELICAL PEPTIDES AND METHODS OF SYNTHESIS THE UNIVERSITY OF HONG KONG (CN) 2017-06-08 WO disclosed
US-20170152286-A1 STAPLED HELICAL PEPTIDES AND METHODS OF SYNTHESIS THE UNIVERSITY OF HONG KONG (HK) 2017-06-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10011631-B2 Stapled helical peptides and methods of synthesis SPPL2B, SUCLA2, PRAP1 ACHE 4823/4885ALDH1A1 2914/4885MAPK1 2897/4885
US-10954287-B2 Ras binding peptides and methods of use KRAS, RASGRP1, NRAS ACHE 4743/4885ALDH1A1 4777/4885MAPK1 248/4885
US-20170152286-A1 STAPLED HELICAL PEPTIDES AND METHODS OF SYNTHESIS SPPL2B, SUCLA2, PRAP1 ACHE 4823/4885ALDH1A1 2914/4885MAPK1 2897/4885
US-20190119358-A1 RAS BINDING PEPTIDES AND METHODS OF USE KRAS, RASGRP1, NRAS ACHE 4743/4885ALDH1A1 4777/4885MAPK1 248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.